News Releases

DateTitle 
10/18/19
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive trend vote on the Marketing Authorization Application
10/16/19
Call will feature presentation by key opinion leader in the treatment of chronic ITP SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today announced that it will host a conference call and webcast for investors and analysts on Wednesday,
10/02/19
Receives $9 million in payments from collaborations     SOUTH SAN FRANCISCO , Oct. 2, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a $60 million term loan credit facility with MidCap Financial ("MidCap").
09/23/19
  SOUTH SAN FRANCISCO, Calif. , Sept. 23, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. ("Kissei"), has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult patients with
08/28/19
SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled to participate in a panel discussion at Citi's 14 th Annual Biotech Conference in Boston,
08/06/19
TAVALISSE® net product sales increased 26% quarter over quarter to $10.2 million First patients enrolled in Phase 3 pivotal trial of TAVALISSE in warm autoimmune hemolytic anemia (AIHA) Conference call and webcast today at 4:30PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug.
07/30/19
SOUTH SAN FRANCISCO , July 30, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2019 financial results after market close on Tuesday, August 6 , 2019.  Rigel senior management will follow the announcement with a live conference
06/13/19
SOUTH SAN FRANCISCO , June 13, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters at the 24 th Congress of the European Hematology Association (EHA) in Amsterdam, The
05/31/19
SOUTH SAN FRANCISCO, Calif. , May 31, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 Healthcare Conference in New York City on Wednesday,
05/16/19
Announces resignation of Chief Medical Officer effective August 31, 2019 SOUTH SAN FRANCISCO, Calif. , May 16, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium
05/07/19
TAVALISSE® net product sales of $8.1 million on 1,019 bottles, a 10% increase quarter-over-quarter Total revenues of $12.6 million, including $4.6 million from collaborations Opened clinical trial sites for Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (AIHA); expect to enroll
04/30/19
SOUTH SAN FRANCISCO, Calif. , April 30, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2019 financial results after market close on Tuesday, May 7 , 2019.  Rigel senior management will follow the announcement with a live
03/26/19
Peter S. Ringrose, Ph.D. Retires from Board Position SOUTH SAN FRANCISCO, Calif. , March 26, 2019 /PRNewswire/ -- Rigel Pharmaceuticals , Inc. (Nasdaq: RIGL) today announced that it has appointed Jane Wasman to its board of directors. Ms. Wasman is a strategic leader with over 20 years of
02/28/19
Fourth quarter total revenues of $37.9 million; full year total revenues of $44.5 million Fourth quarter net product sales of $7.3 million; full year net product sales of $13.9 million Conference call and webcast today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Feb.
02/21/19
SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2018 financial results after market close on Thursday, February 28 , 2019.  Rigel senior management will follow the announcement
01/23/19
- Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million, with the potential for $297.5 million in total regulatory and commercial milestones - Potential milestones to Rigel include a $20 million payment
01/07/19
Reports 1,794 total bottles of TAVALISSE™ (fostamatinib disodium hexahydrate) sold in 2018 SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq: RIGL) today provided a business update, including the quantity of TAVALISSE™ bottles sold in 2018 and its cash
01/03/19
SOUTH SAN FRANCISCO , Jan. 3, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, is scheduled to present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at